2016 Investment Forum Company Presentations
2016 Translational Partners Investment Forum
Presenting companies:
AMP3D has developed a platform for analytics and displays that makes sense of “Big Data” in health care in real time.
Apollo Medical Devices is commercializing a diagnostic biosensor technology. Using a single drop of blood, Apollo’s proprietary technology platform delivers patient blood chemistry test results from a portable analyzer at the patient’s bedside.
Ardent Cell Technologies is developing a point-of-care, minimally-invasive procedure that provides a safe, effective, and convenient way to promote healthy fat loss and treat diabetes symptoms.
Breath Diagnostics has developed OneBreath, a simple, non-invasive breath test for the early detection of lung cancer.
Constant Therapy is a cloud based mobile solution that helps people improve their brain function & learning after a brain injury, stroke, diagnosis of learning disorders or dementia.
Glyscend is developing a treatment for type 2 diabetes that involves a proprietary formulation, taken once a day, that inhibits stimulation of neurohormonal signals from the proximal gut, resulting in diabetes remission.
HistoSonics is leading the revolution in histotripsy, a non-invasive, non-thermal surgery that will reduce patient trauma and healthcare costs across multiple clinical indications.
i-Function is developing a cutting edge evidence & technology-based functional skills assessment and training package that addresses cognitive impairment, both age-related and from other source.
LifeSprout is developing advanced solutions to restore and enhance soft tissues, utilizing its nanofiber-hydrogel technology to effect lasting, natural, tissue augmentation.
Meditopian is developing innovative point-of-care diagnostics requiring only a drop of blood to provide actionable information, unavailable today, which will impact millions of lives in the underserved world.
MiMecore Therapeutics LLC is a glycobiologics company developing a novel suite of biomimetic proteoglycans (BPGs) with the potential to provide a ground-breaking therapeutic approach for the repair of degenerated soft and connective tissues.
Moving Analytics helps hospitals implement home based cardiac rehab programs delivered through patient’s mobile devices, helping hospitals increase patient enrollment, generate additional revenue and reduce readmission.
Nanopore Diagnostics aims to halt the costly misuse of antibiotics with a 30-minute test that will ensure physicians know exactly what they are treating before making an antibiotic decision.
NanoScint offers innovative detectors for monitoring radiation in medical, safety and defense situations.
Nexgenia develops and synthesizes proprietary stimuli-sensitive (“smart”) polymers that enable the development of rapid, efficient, and sensitive processes for molecular purifications, cellular separations, and diagnostic assays.
Optofluidic Bioassay has a novel microfluidic 96-well ELISA (enzyme-linked immunosorbet assay) plate with demonstrated superior results in sample size, workflow and assay time using standard ELISA tests against a standard 96-well plate.
Pelvalon is commercializing the Eclipse System for treating fecal incontinence (FI).
PIVOT is a rehabilitation technology company. Our first offering, PIVOT, non-invasively quantifies the stability of the anterior cruciate ligament (ACL) in the knee and classifies the degree of injury.
PolyCore Therapeutics LLC is a drug development company focused on products for CNS disorders such as a first-in-class therapeutic to treat motor symptoms and reverse cognitive impairment of Parkinson’s disease.
PromiSight’s vision is to become the leader in cataract prevention using HydroLenZ, a unique gel that prevents the formation of post-vitrectomy cataracts, eliminating the need for Intraocular Lens Implant (IOL) procedures.
Quicksilver is developing an electronic, solid state, scalable single-molecule detection platform with the potential to revolutionize biological sensors.
RxMP Therapeutics, LLC is an emerging pharmaceutical company developing novel hemostatic agents that are designed to arrest or prevent excessive bleeding, thus reducing the need for transfused blood.
Shape Memory Therapeutics
Shape Memory Therapeutics is commercializing vascular occlusion and embolization devices based on a biointegrative shape memory polymer matrix technology to treat pathologies in the peripheral and cerebral vasculature.
SkinJect, Inc. is developing a novel approach to treat and prevent non-melanoma skin cancers using a dissolvable microneedle array technology to deliver topical chemotherapy, killing tumor cells and immunizing patients against recurrence.
Stasys Medical Corp is developing the first rapid, complete, accurate point-of-care platelet function device using patented technology that mimics the in vivo clotting process to reduce healthcare costs and save lives.
TypeZero builds personalized analytics and control solutions based upon proven metabolic models to help people with diabetes improve health outcomes and reduce stress while dramatically reducing cost of treatment.
Zebra Medical Technologies
Zebra Medical Technologies, Inc. has created the first live tissue cellular pathology system enabling non-invasive, point-of-care imaging of skin cancers to improve diagnoses and highlight surgical margins prior to excision.